| Literature DB >> 15948774 |
C van Drunen1, E O Meltzer, C Bachert, J Bousquet, W J Fokkens.
Abstract
Mometasone furoate nasal spray (MFNS; Nasonex, Schering-Plough Corporation, Kenilworth, NJ, USA) is an effective and well-tolerated intranasal corticosteroid approved for the prophylactic treatment of seasonal allergic rhinitis, and the treatment of perennial allergic rhinitis. MFNS is a potent molecule with a rapid onset of action and excellent safety and efficacy profiles. Having recently received approval for the treatment of nasal polyposis, data indicate that MFNS may also be effective in rhinosinusitis.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15948774 DOI： 10.1111/j.1398-9995.2005.00917.x
Source DB: PubMed Journal: Allergy ISSN： 0105-4538 Impact factor: 13.146